Chadi Nabhan

2.3k total citations
97 papers, 1.5k citations indexed

About

Chadi Nabhan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Chadi Nabhan has authored 97 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 20 papers in Molecular Biology. Recurrent topics in Chadi Nabhan's work include Prostate Cancer Treatment and Research (27 papers), Lymphoma Diagnosis and Treatment (13 papers) and Cancer Genomics and Diagnostics (11 papers). Chadi Nabhan is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Lymphoma Diagnosis and Treatment (13 papers) and Cancer Genomics and Diagnostics (11 papers). Chadi Nabhan collaborates with scholars based in United States, Italy and Austria. Chadi Nabhan's co-authors include Martin S. Tallman, Jacob M. Rowe, James H. Feusner, Adam M. Petrich, Timothy M. Lestingi, Bruce A. Feinberg, Andrew J. Klink, Jayesh Mehta, Vinay Prasad and Jacob D. Bitran and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chadi Nabhan

92 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chadi Nabhan United States 20 609 505 388 332 211 97 1.5k
Mark D. Rothmann United States 16 445 0.7× 443 0.9× 508 1.3× 324 1.0× 154 0.7× 46 1.9k
Phuong K. Morrow United States 24 525 0.9× 1.0k 2.1× 198 0.5× 396 1.2× 181 0.9× 65 1.8k
William J. Edenfield United States 19 674 1.1× 783 1.6× 661 1.7× 741 2.2× 179 0.8× 101 2.1k
Jeffrey P. Hodge United States 20 794 1.3× 1.3k 2.5× 203 0.5× 566 1.7× 230 1.1× 39 2.3k
Nicole Gormley United States 18 272 0.4× 362 0.7× 397 1.0× 90 0.3× 110 0.5× 53 1.0k
Sandeep Padala United States 10 658 1.1× 532 1.1× 158 0.4× 687 2.1× 173 0.8× 40 1.8k
Alan Barge United Kingdom 14 411 0.7× 819 1.6× 664 1.7× 250 0.8× 179 0.8× 21 1.5k
N Stuart United Kingdom 18 781 1.3× 744 1.5× 177 0.5× 232 0.7× 141 0.7× 36 1.9k
Karina Vera United States 10 816 1.3× 723 1.4× 158 0.4× 762 2.3× 142 0.7× 17 1.7k
José Luís Passos‐Coelho Portugal 21 273 0.4× 913 1.8× 279 0.7× 288 0.9× 84 0.4× 46 1.4k

Countries citing papers authored by Chadi Nabhan

Since Specialization
Citations

This map shows the geographic impact of Chadi Nabhan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chadi Nabhan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chadi Nabhan more than expected).

Fields of papers citing papers by Chadi Nabhan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chadi Nabhan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chadi Nabhan. The network helps show where Chadi Nabhan may publish in the future.

Co-authorship network of co-authors of Chadi Nabhan

This figure shows the co-authorship network connecting the top 25 collaborators of Chadi Nabhan. A scholar is included among the top collaborators of Chadi Nabhan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chadi Nabhan. Chadi Nabhan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Choi, Sharon H., Elizabeth Pan, Andrew Elliott, et al.. (2024). Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer. Molecular Cancer Research. 22(10). 920–931. 1 indexed citations
3.
Meagher, Margaret, Andrew Elliott, Alex Farrell, et al.. (2024). Characterization and impact of non‐canonical WNT signaling on outcomes of urothelial carcinoma. Cancer Medicine. 13(7). e7148–e7148.
4.
Bagrodia, Aditya, Liwei Jia, Alex Farrell, et al.. (2023). The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.. Journal of Clinical Oncology. 41(16_suppl). 5007–5007. 1 indexed citations
5.
Deshmukh, Sachin Kumar, Sharon Wu, Joanne Xiu, et al.. (2023). Characterizing the role of PIM kinases in the prostate tumor immune microenvironment.. Journal of Clinical Oncology. 41(16_suppl). e17080–e17080. 1 indexed citations
6.
7.
Seeber, Andreas, Florian Kocher, Alberto Puccini, et al.. (2020). Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open. 5(6). e000942–e000942. 32 indexed citations
8.
Gajra, Ajeet, et al.. (2020). Frequency and Causes of Burnout in US Community Oncologists in the Era of Electronic Health Records. JCO Oncology Practice. 16(4). e357–e365. 17 indexed citations
9.
Schoen, Martin W., Shamia Hoque, Benjamin Schooley, et al.. (2020). End of an era for erythropoiesis‐stimulating agents in oncology. International Journal of Cancer. 146(10). 2829–2835. 8 indexed citations
10.
11.
Feinberg, Bruce A., et al.. (2017). CAR-T cells: the next era in immuno-oncology.. PubMed. 23(2 Spec No.). SP48–SP52. 2 indexed citations
12.
George, Daniel J., Chadi Nabhan, Todd DeVries, James B. Whitmore, & Leonard G. Gomella. (2015). Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. Cancer Immunology Research. 3(9). 1063–1069. 19 indexed citations
13.
Meyer, Andrew, et al.. (2013). Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 12(2). 100–105. 13 indexed citations
14.
15.
16.
Nabhan, Chadi, Nancy Davis, Jacob D. Bitran, et al.. (2010). Efficacy and safety of clofarabine in relapsed and/or refractory non‐hodgkin lymphoma, including rituximab‐refractory patients. Cancer. 117(7). 1490–1497. 13 indexed citations
17.
Radhakrishnan, Amruta, et al.. (2009). Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial. Journal of Chemotherapy. 21(4). 439–444. 6 indexed citations
18.
Nabhan, Chadi. (2006). A Simple Wish…Unfulfilled. Journal of Clinical Oncology. 24(7). 1217–1218.
19.
Nabhan, Chadi, et al.. (2004). Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Annals of Oncology. 15(8). 1231–1236. 20 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark D. Rothmann Breakdown of academic impact, for papers by Phuong K. Morrow Breakdown of academic impact, for papers by William J. Edenfield Breakdown of academic impact, for papers by Jeffrey P. Hodge Breakdown of academic impact, for papers by Nicole Gormley Breakdown of academic impact, for papers by Sandeep Padala Breakdown of academic impact, for papers by Alan Barge Breakdown of academic impact, for papers by N Stuart Breakdown of academic impact, for papers by Karina Vera Breakdown of academic impact, for papers by José Luís Passos‐Coelho
Rankless by CCL
2026